Stanley Laman Group Ltd. Sells 12,274 Shares of CVS Health Corporation $CVS

Stanley Laman Group Ltd. decreased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 15.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,253 shares of the pharmacy operator’s stock after selling 12,274 shares during the quarter. Stanley Laman Group Ltd.’s holdings in CVS Health were worth $4,639,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. Goldman Sachs Group Inc. grew its holdings in shares of CVS Health by 87.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock valued at $672,598,000 after acquiring an additional 4,632,530 shares in the last quarter. Dodge & Cox boosted its position in CVS Health by 4.8% during the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares during the last quarter. Nuveen LLC bought a new position in CVS Health in the first quarter valued at approximately $204,421,000. Invesco Ltd. increased its position in shares of CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after purchasing an additional 2,375,764 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its stake in shares of CVS Health by 815.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock worth $183,701,000 after purchasing an additional 2,372,121 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Up 1.6%

Shares of CVS opened at $82.64 on Friday. The firm has a market cap of $104.81 billion, a P/E ratio of 23.08, a price-to-earnings-growth ratio of 0.90 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $82.88. The firm’s 50-day simple moving average is $74.00 and its 200 day simple moving average is $68.12.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same period last year, the business posted $1.83 earnings per share. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.2%. CVS Health’s dividend payout ratio (DPR) is presently 74.30%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CVS. Cantor Fitzgerald reissued an “overweight” rating and issued a $78.00 target price on shares of CVS Health in a research note on Tuesday, August 26th. Wells Fargo & Company lifted their price objective on shares of CVS Health from $84.00 to $103.00 and gave the company an “overweight” rating in a research report on Tuesday, October 7th. Truist Financial set a $92.00 target price on shares of CVS Health in a report on Tuesday. Mizuho raised their target price on shares of CVS Health from $76.00 to $88.00 and gave the company an “outperform” rating in a research note on Thursday, October 9th. Finally, Wolfe Research boosted their price target on CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $82.57.

Insider Buying and Selling at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.22% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.